The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis : Data From the Simtuzumab Trials
© 2019 by the American Association for the Study of Liver Diseases..
Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridging fibrosis (F3) or compensated cirrhosis (F4) enrolled in two phase 2b, placebo-controlled trials of simtuzumab. The trials were terminated after 96 weeks because of lack of efficacy, so data from treatment groups were combined. Liver biopsies and HVPG measurements (only for patients with F4 fibrosis) were collected at screening and at weeks 48 and 96. Patients were assessed for Ishak fibrosis stage, hepatic collagen content and alpha-smooth muscle actin (by morphometry), NAFLD Activity Score (NAS), and serum markers of fibrosis. Associations with progression to cirrhosis (in patients with F3 fibrosis) and liver-related clinical events (in patients with F4 fibrosis) were determined. Progression to cirrhosis occurred in 22% (48/217) of F3 patients, and liver-related clinical events occurred in 19% (50/258) of patients with cirrhosis. Factors significantly associated with progression to cirrhosis included higher baseline values of and greater increases in hepatic collagen content, level of alpha-smooth muscle actin, and Enhanced Liver Fibrosis score. Similar factors, plus lack of fibrosis stage improvement (hazard ratio, 9.30; 95% confidence interval, 1.28-67.37), higher HVPG at baseline, and greater increase in HVPG over time, were associated with an increased risk of liver-related clinical events in patients with cirrhosis. Disease progression was not associated with the NAS at baseline or changes in NAS during treatment after adjustment for fibrosis stage. Conclusion: In patients with advanced fibrosis due to NASH, the primary determinant of clinical disease progression is fibrosis and its change over time.
| Errataetall: |
CommentIn: Hepatology. 2019 Dec;70(6):1885-1888. - PMID 31520407 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Hepatology (Baltimore, Md.) - 70(2019), 6 vom: 30. Dez., Seite 1913-1927 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sanyal, Arun J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
11Z5AIU653 |
|---|
| Anmerkungen: |
Date Completed 29.06.2020 Date Revised 29.06.2020 published: Print-Electronic CommentIn: Hepatology. 2019 Dec;70(6):1885-1888. - PMID 31520407 Citation Status MEDLINE |
|---|
| doi: |
10.1002/hep.30664 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM296144274 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM296144274 | ||
| 003 | DE-627 | ||
| 005 | 20231225085212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hep.30664 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0987.xml |
| 035 | |a (DE-627)NLM296144274 | ||
| 035 | |a (NLM)30993748 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanyal, Arun J |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis |b Data From the Simtuzumab Trials |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2020 | ||
| 500 | |a Date Revised 29.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Hepatology. 2019 Dec;70(6):1885-1888. - PMID 31520407 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 by the American Association for the Study of Liver Diseases. | ||
| 520 | |a Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridging fibrosis (F3) or compensated cirrhosis (F4) enrolled in two phase 2b, placebo-controlled trials of simtuzumab. The trials were terminated after 96 weeks because of lack of efficacy, so data from treatment groups were combined. Liver biopsies and HVPG measurements (only for patients with F4 fibrosis) were collected at screening and at weeks 48 and 96. Patients were assessed for Ishak fibrosis stage, hepatic collagen content and alpha-smooth muscle actin (by morphometry), NAFLD Activity Score (NAS), and serum markers of fibrosis. Associations with progression to cirrhosis (in patients with F3 fibrosis) and liver-related clinical events (in patients with F4 fibrosis) were determined. Progression to cirrhosis occurred in 22% (48/217) of F3 patients, and liver-related clinical events occurred in 19% (50/258) of patients with cirrhosis. Factors significantly associated with progression to cirrhosis included higher baseline values of and greater increases in hepatic collagen content, level of alpha-smooth muscle actin, and Enhanced Liver Fibrosis score. Similar factors, plus lack of fibrosis stage improvement (hazard ratio, 9.30; 95% confidence interval, 1.28-67.37), higher HVPG at baseline, and greater increase in HVPG over time, were associated with an increased risk of liver-related clinical events in patients with cirrhosis. Disease progression was not associated with the NAS at baseline or changes in NAS during treatment after adjustment for fibrosis stage. Conclusion: In patients with advanced fibrosis due to NASH, the primary determinant of clinical disease progression is fibrosis and its change over time | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a ACTA2 protein, human |2 NLM | |
| 650 | 7 | |a Actins |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a simtuzumab |2 NLM | |
| 650 | 7 | |a 11Z5AIU653 |2 NLM | |
| 700 | 1 | |a Harrison, Stephen A |e verfasserin |4 aut | |
| 700 | 1 | |a Ratziu, Vlad |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelmalek, Manal F |e verfasserin |4 aut | |
| 700 | 1 | |a Diehl, Anna Mae |e verfasserin |4 aut | |
| 700 | 1 | |a Caldwell, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Shiffman, Mitchell L |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilar Schall, Raul |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a McColgan, Bryan |e verfasserin |4 aut | |
| 700 | 1 | |a Djedjos, C Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a McHutchison, John G |e verfasserin |4 aut | |
| 700 | 1 | |a Subramanian, G Mani |e verfasserin |4 aut | |
| 700 | 1 | |a Myers, Robert P |e verfasserin |4 aut | |
| 700 | 1 | |a Younossi, Zobair |e verfasserin |4 aut | |
| 700 | 1 | |a Muir, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Afdhal, Nezam H |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Zachary |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology (Baltimore, Md.) |d 1983 |g 70(2019), 6 vom: 30. Dez., Seite 1913-1927 |w (DE-627)NLM012603902 |x 1527-3350 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2019 |g number:6 |g day:30 |g month:12 |g pages:1913-1927 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hep.30664 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2019 |e 6 |b 30 |c 12 |h 1913-1927 | ||